<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cav" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cav</book-part-id>
      <title-group>
        <title>Caveolinopathies</title>
        <alt-title alt-title-type="alt-title">Synonym: Caveolin-3 Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Bruno</surname>
            <given-names>Claudio</given-names>
          </name>
          <xref ref-type="aff" rid="cav.AFF1"/>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Sotgia</surname>
            <given-names>Federica</given-names>
          </name>
          <xref ref-type="aff" rid="cav.AFF2"/>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Gazzerro</surname>
            <given-names>Elisabetta</given-names>
          </name>
          <xref ref-type="aff" rid="cav.AFF3"/>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Minetti</surname>
            <given-names>Carlo</given-names>
          </name>
          <xref ref-type="aff" rid="cav.AFF4"/>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Lisanti</surname>
            <given-names>Michael P</given-names>
          </name>
          <xref ref-type="aff" rid="cav.AFF5"/>
          <degrees>MD, PhD</degrees>
        </contrib>
      </contrib-group>
      <aff id="cav.AFF1">Department of Pediatrics, Neuromuscular Disease Unit <break/>Gaslini Pediatric Hospital <break/>University of Genova<break/>Genova, Italy</aff>
      <aff id="cav.AFF2">Department of Biochemistry and Molecular Biology, Jefferson Medical College <break/>Department of Cancer Biology, Kimmel Cancer Center <break/>Thomas Jefferson University<break/>Philadelphia, Pennsylvania</aff>
      <aff id="cav.AFF3">Department of Pediatrics, Neuromuscular Disease Unit <break/>Gaslini Pediatric Hospital <break/>University of Genova<break/>Genova, Italy</aff>
      <aff id="cav.AFF4">Department of Pediatrics, Neuromuscular Disease Unit <break/>Gaslini Pediatric Hospital <break/>University of Genova<break/>Genova, Italy</aff>
      <aff id="cav.AFF5">Department of Biochemistry and Molecular Biology, Jefferson Medical College<break/>Department of Cancer Biology, Kimmel Cancer Center <break/>Thomas Jefferson University<break/>Philadelphia, Pennsylvania</aff>
      <pub-history>
        <date iso-8601-date="2007-05-14" date-type="created">
          <day>14</day>
          <month>05</month>
          <year>2007</year>
        </date>
        <date iso-8601-date="2012-09-06" date-type="updated">
          <day>06</day>
          <month>09</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cvt" document-type="chapter">Catecholaminergic Polymorphic Ventricular Tachycardia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="celiac" document-type="chapter">Celiac Disease</related-object>
      <abstract id="cav.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The caveolinopathies, a group of muscle diseases, can be classified into five phenotypes, which can be seen in different members of the same family: </p>
          <list list-type="bullet">
            <list-item>
              <p>Limb-girdle muscular dystrophy 1C (LGMD1C), characterized by onset usually in the first decade, mild-to-moderate proximal muscle weakness, calf hypertrophy, positive Gower sign, and variable muscle cramps after exercise </p>
            </list-item>
            <list-item>
              <p>Isolated hyperCKemia (i.e., elevated serum concentration of creatine kinase (CK) in the absence of signs of muscle disease) (HCK)</p>
            </list-item>
            <list-item>
              <p>Rippling muscle disease (RMD), characterized by signs of increased muscle irritability, such as percussion-induced rapid contraction (PIRC), percussion-induced muscle mounding (PIMM), and/or electrically silent muscle contractions (rippling muscle)</p>
            </list-item>
            <list-item>
              <p>Distal myopathy (DM), observed in one individual only </p>
            </list-item>
            <list-item>
              <p>Hypertrophic cardiomyopathy (HCM), without skeletal muscle manifestations</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p><italic toggle="yes">CAV3</italic>, which encodes caveolin-3, a muscle-specific membrane protein and the principal component of caveolae membrane in muscle cells in vivo, is the only gene in which mutations are known to cause caveolinopathies. Sequence analysis identifies mutations in more than 99% of affected individuals. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Aggressive supportive care to preserve muscle function, maximize functional ability and treat complications, especially in those with the LGMD phenotype; weight control to avoid obesity; physical therapy and stretching exercises to promote mobility and prevent contractures; use of mechanical aids such as canes, walkers, orthotics, and wheelchairs as needed to help ambulation and mobility; social and emotional support. </p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> In individuals with isolated HCK, special precautions during surgical procedures and anesthesia because of possible risk for malignant hyperthermia (MH). </p>
          <p><italic toggle="yes">Surveillance:</italic> Periodic monitoring of spine, respiratory function, cardiac function, mobility, and muscle function based on individual needs.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Most caveolinopathies are inherited in an autosomal dominant manner; they may also be inherited in an autosomal recessive manner. </p>
          <p><italic toggle="yes">Autosomal dominant caveolinopathies</italic>: Most affected individuals have an affected parent; the proportion of cases caused by <italic toggle="yes">de novo</italic> mutations is unknown, but probably rare. Each child of an individual with an autosomal dominant caveolinopathy has a 50% chance of inheriting the mutation. </p>
          <p><italic toggle="yes">Autosomal recessive caveolinopathies:</italic> The parents of an affected child are obligate heterozygotes (carriers) and therefore carry one mutant allele; heterozygotes can be asymptomatic or can display modest elevation of serum CK concentration and/or calf hypertrophy. At conception, each sib of an individual with autosomal recessive caveolinopathy has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing is possible if both disease-causing mutations have been identified in the family.</p>
          <p>Prenatal testing for pregnancies at increased risk is possible if the disease-causing mutation(s) have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cav.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="cav.T.nc_caveolinopathies_included_disor" position="anchor" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <th id="hd_b_cav.T.nc_caveolinopathies_included_disor_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Caveolinopathies: Included Disorders&#x000a0;<sup>1</sup></th>
              </tr>
              <tr>
                <td headers="hd_b_cav.T.nc_caveolinopathies_included_disor_1_1_1_1" align="left" valign="top" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Limb-girdle muscular dystrophy 1C</p>
                    </list-item>
                    <list-item>
                      <p>Isolated hyperCKemia</p>
                    </list-item>
                    <list-item>
                      <p>Rippling muscle disease</p>
                    </list-item>
                    <list-item>
                      <p>Distal myopathy</p>
                    </list-item>
                    <list-item>
                      <p>Hypertrophic cardiomyopathy</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="cav.TF.1">
              <label>1.</label>
              <p>Forms of disorders associated with genes other than <italic toggle="yes">CAV3</italic> are not addressed in this <italic toggle="yes">GeneReview</italic>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="cav.Diagnosis">
        <title>Diagnosis</title>
        <sec id="cav.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Caveolinopathies have a wide spectrum of clinical presentations.</p>
          <p><bold>Clinical findings that may support the diagnosis of a caveolinopathy</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Onset usually in the first two decades </p>
            </list-item>
            <list-item>
              <p>Progressive, proximal, symmetrical muscle weakness </p>
            </list-item>
            <list-item>
              <p>Calf hypertrophy </p>
            </list-item>
            <list-item>
              <p>Myalgia, cramps, and/or stiffness after exercise </p>
            </list-item>
            <list-item>
              <p>Muscle hyperirritability manifest as: </p>
              <list list-type="bullet">
                <list-item>
                  <p>Percussion-induced rapid contraction (PIRC) in which tapping the muscle belly results in rapid contraction of the muscle;</p>
                </list-item>
                <list-item>
                  <p>Percussion-induced muscle mounding (PIMM) in which a visible localized swelling of the muscle is caused by contraction at the point of contact;</p>
                </list-item>
                <list-item>
                  <p>Muscle rippling - a silent (absence of action potentials) wave of muscle contractions that occurs on mechanical stretching of the muscle. </p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Positive Gowers sign </p>
            </list-item>
          </list>
          <p><bold>Biochemical studies.</bold> Elevated serum creatine kinase (CK) concentration ranging from 450 to 5000 U/L (normal upper limit: 150 U/L) </p>
          <p><bold>Electrophysiologic studies.</bold> Electromyography (EMG) ranging from normal to a myopathic pattern. In some cases, muscle activity is electrically silent. </p>
          <p><bold>Muscle biopsy</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Histology.</bold> Typical findings in the five phenotypes caused by <italic toggle="yes">CAV3</italic> mutations may be normal or may include variability in fiber size, degenerating/regenerating muscle fibers with an increased number of central nuclei, and a mild increase in connective tissue. Phenotype-specific findings include the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>LGMD1C.</bold> Muscle biopsy showed nonspecific myopathic changes with scattered necrotic fibers and increased connective tissue [<xref ref-type="bibr" rid="cav.REF.minetti.1998.365">Minetti et al 1998</xref>]. Other studies found variably sized, degenerating/regenerating muscle fibers with an increased number of central nuclei and a mild increase in connective tissue [<xref ref-type="bibr" rid="cav.REF.kunkel.1999.33">Kunkel 1999</xref>, <xref ref-type="bibr" rid="cav.REF.herrmann.2000.2335">Herrmann et al 2000</xref>, <xref ref-type="bibr" rid="cav.REF.figarellabranger.2003.562">Figarella-Branger et al 2003</xref>]. </p>
                </list-item>
                <list-item>
                  <p><bold>Isolated hyperckemia (HCK).</bold>
<xref ref-type="bibr" rid="cav.REF.carbone.2000.1373">Carbone et al [2000]</xref> found only mild fiber size variability in an Italian child. The expression of caveolin-3 was reduced both by immunohistochemistry and immunoblot analysis in muscle fibers. In a study of two members of an Italian family with HCK, muscle biopsy revealed a partial caveolin-3 deficiency [<xref ref-type="bibr" rid="cav.REF.merlini.2002.65">Merlini et al 2002</xref>].</p>
                </list-item>
                <list-item>
                  <p><bold>Rippling muscle disease (RMD).</bold> In a study of five families with RMD, muscle biopsy showed increases in fiber size variability, centralized nuclei, and a mild type-1 fiber predominance [<xref ref-type="bibr" rid="cav.REF.betz.2001.218">Betz et al 2001</xref>]. </p>
                </list-item>
                <list-item>
                  <p><bold>Distal myopathy (DM).</bold> Histologic analysis of the biceps brachii in a 25-year-old affected Japanese woman showed mild variation in fiber size, an increased number of centralized nuclei, and a predominance of type 1 fibers. Caveolin-3 was markedly reduced using both immunohistochemistry and immunoblot analysis in muscle fibers [<xref ref-type="bibr" rid="cav.REF.tateyama.2002.323">Tateyama et al 2002</xref>].Note: Individuals affected by hyperCKemia or hypertrophic cardiomyopathy often display normal muscle histology. </p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Ultrastructural analysis.</bold> Loss of caveolae at the sarcolemma, large sub-sarcolemmal membrane vacuoles, and "honeycomb" membranous structures</p>
            </list-item>
            <list-item>
              <p><bold>Immunohistochemical</bold> staining of skeletal muscle biopsy</p>
              <list list-type="bullet">
                <list-item>
                  <p>Anti-caveolin-3 antibodies: reduced or nearly complete absence of caveolin-3 immuno-reactivity on the plasma membrane </p>
                </list-item>
                <list-item>
                  <p>Dysferlin membrane staining: reduced or altered (Instead of a uniform immunostaining on the plasma membrane, dysferlin exhibits a "patchy-like" distribution, and accumulates in the cytoplasm.) </p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Western immunoblot analysis</bold> of skeletal muscle biopsy. Quantitative caveolin-3 protein levels range from less than 5% to 35% of normal. </p>
            </list-item>
          </list>
        </sec>
        <sec id="cav.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">CAV3</italic>, which encodes caveolin-3, a muscle-specific membrane protein and the principal component of caveolae membrane in muscle cells in vivo, is the only gene in which mutations are known to cause caveolinopathies. </p>
          <p><bold>Clinical testing</bold>
</p>
          <table-wrap id="cav.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Caveolinopathies</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Mutations Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
                <tr>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1">
                    <italic toggle="yes">CAV3</italic>
                  </td>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;99%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Exonic or whole-gene deletions&#x000a0;<sup>7</sup></td>
                  <td headers="hd_b_cav.T.summary_of_molecular_genetic_testi_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Unknown</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cav.TF.2">
                <label>1.</label>
                <p>See <related-object source-id="gene" document-id="cav" object-id="cav.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. </p>
              </fn>
              <fn id="cav.TF.2.1">
                <label>2.</label>
                <p>See <xref ref-type="sec" rid="cav.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="cav.TF.2.2">
                <label>3.</label>
                <p>The ability of the test method used to detect a mutation that is present in the indicated gene</p>
              </fn>
              <fn id="cav.TF.2.3">
                <label>4.</label>
                <p>Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="cav.TF.2.4">
                <label>5.</label>
                <p>
                  <xref ref-type="bibr" rid="cav.REF.woodman.2004.538">Woodman et al [2004]</xref>
                </p>
              </fn>
              <fn id="cav.TF.2.5">
                <label>6.</label>
                <p>Testing that identifies exonic or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="cav.TF.2.6">
                <label>7.</label>
                <p>
                  <xref ref-type="bibr" rid="cav.REF.traverso.2008.735">Traverso et al [2008]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="cav.Testing_Strategy">
          <title>Testing Strategy </title>
          <p><bold>To confirm/establish the diagnosis in a proband</bold> whose clinical findings suggest the diagnosis of a caveolinopathy: </p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Obtain serum CK concentration.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Obtain muscle biopsy for histologic evaluation, ultrastructural analysis, and immunohistochemical staining.</p>
            </list-item>
            <list-item>
              <label>3</label>
              <p>In those with findings consistent with a caveolinopathy, perform molecular genetic testing of CAV. </p>
            </list-item>
          </list>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the disease-causing mutation(s) in the family.</p>
        </sec>
      </sec>
      <sec id="cav.Clinical_Description">
        <title>Clinical Characteristics</title>
        <p>
          <bold>Natural History</bold>
        </p>
        <p>The caveolinopathies are a clinically heterogeneous group of muscle diseases that can be classified into the five following phenotypes [<xref ref-type="bibr" rid="cav.REF.cagliani.2003.1513">Cagliani et al 2003</xref>, <xref ref-type="bibr" rid="cav.REF.woodman.2004.538">Woodman et al 2004</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p>Limb-girdle muscular dystrophy 1C (LGMD1C) </p>
          </list-item>
          <list-item>
            <p>Isolated hyperCKemia (i.e., in the absence of any signs of muscle disease) (HCK) </p>
          </list-item>
          <list-item>
            <p>Rippling muscle disease (RMD) </p>
          </list-item>
          <list-item>
            <p>Distal myopathy (DM) </p>
          </list-item>
          <list-item>
            <p>Hypertrophic cardiomyopathy (HCM) </p>
          </list-item>
        </list>
        <p>The five phenotypes are not family specific: families with overlapping phenotypes have been reported [<xref ref-type="bibr" rid="cav.REF.cagliani.2003.1513">Cagliani et al 2003</xref>, <xref ref-type="bibr" rid="cav.REF.woodman.2004.538">Woodman et al 2004</xref>]. </p>
        <p>Myalgia is a common presenting symptom [<xref ref-type="bibr" rid="cav.REF.aboumoussa.2008.572">Aboumoussa et al 2008</xref>].</p>
        <p><bold>Limb-girdle muscular dystrophy 1C (LGMD1C).</bold> In the report of <xref ref-type="bibr" rid="cav.REF.minetti.1998.365">Minetti et al [1998]</xref> affected individuals in two unrelated Italian families had onset of symptoms at approximately age five years including mild-to-moderate proximal muscle weakness, calf hypertrophy, positive Gower sign, and serum CK concentrations approximately four- to 25-fold higher than normal. Two individuals from the same family had muscle cramps after exercise. </p>
        <p>Subsequent reports included: </p>
        <list list-type="bullet">
          <list-item>
            <p>A German girl age four years with myalgia and muscle cramps in the lower limbs but no muscle weakness [<xref ref-type="bibr" rid="cav.REF.kunkel.1999.33">Kunkel 1999</xref>]; </p>
          </list-item>
          <list-item>
            <p>A Japanese girl age 11 years with a history of floppiness at birth, marginally delayed motor milestones, progressive proximal muscle weakness, and exercise-induced myalgia [<xref ref-type="bibr" rid="cav.REF.herrmann.2000.2335">Herrmann et al 2000</xref>]; </p>
          </list-item>
          <list-item>
            <p>A woman age 71 years without any previous neuromuscular symptoms, who had mild proximal muscle weakness, scapular winging, slight calf hypertrophy, and a positive Gower sign [<xref ref-type="bibr" rid="cav.REF.figarellabranger.2003.562">Figarella-Branger et al 2003</xref>].</p>
          </list-item>
        </list>
        <p>Two additional unrelated Japanese families with LGMD1C have been reported [<xref ref-type="bibr" rid="cav.REF.sugie.2004.810">Sugie et al 2004</xref>].</p>
        <p><bold>Isolated hyperckemia (HCK)</bold> (i.e., increased serum concentration of CK in the absence of any clinical findings of muscular disease) can be familial or can occur in simplex cases (i.e., a single occurrence in a family). </p>
        <p>In two unrelated Italian children (age 4 and 6 years), the sole finding was variable but persistent hyperCKemia (~4- to 8-fold higher than normal) [<xref ref-type="bibr" rid="cav.REF.carbone.2000.1373">Carbone et al 2000</xref>].</p>
        <p>In two members of an Italian family (the proband and his mother), persistent hyperCKemia was associated with serum CK concentrations that were 17-fold and fourfold higher than normal, respectively, without any signs or symptoms of myopathy [<xref ref-type="bibr" rid="cav.REF.merlini.2002.65">Merlini et al 2002</xref>]. </p>
        <p>In three members of a Spanish family, persistent elevated serum CK concentrations (from 3- to 10-fold higher than normal) without any muscle weakness were reported. Calf hypertrophy was present in the proband [<xref ref-type="bibr" rid="cav.REF.alias.2004.321">Alias et al 2004</xref>].</p>
        <p><bold>Rippling muscle disease (RMD)</bold> is characterized by signs of increased muscle irritability including percussion-induced rapid contraction (PIRC), percussion-induced muscle mounding (PIMM), and/or electrically silent muscle contractions (rippling muscle). </p>
        <p><xref ref-type="bibr" rid="cav.REF.betz.2001.218">Betz et al [2001]</xref> identified <italic toggle="yes">CAV3</italic> mutations in five previously described families with autosomal dominant RMD. In one of the families reported by <xref ref-type="bibr" rid="cav.REF.betz.2001.218">Betz et al [2001]</xref>, five individuals from three generations had late-childhood or early-teen onset of proximal muscle stiffness and PIMM. All had muscle hypertrophy. Seven other relatives had PIMM, but apparently no other muscle symptoms. </p>
        <p><xref ref-type="bibr" rid="cav.REF.vorgerd.2001.2273">Vorgerd et al [2001]</xref> described a man age 24 years, initially evaluated for possible myotonia, who had had painful muscle weakness and cramping since childhood. Family history was negative.</p>
        <p><xref ref-type="bibr" rid="cav.REF.schara.2002.483">Schara et al [2002]</xref> described seven children with RMD and a history of myalgia, muscle cramping, stiffness, and rippling associated with movement starting in early childhood.</p>
        <p>Recently, <xref ref-type="bibr" rid="cav.REF.vandenbergh.2004.1349">Van den Bergh et al [2004]</xref> described a Belgian family in which the proband (age 40 years) complained of fatigue, exercise-induced muscle pain, and muscle cramps from age 35 years. PIRCs were present; muscle rippling was not.</p>
        <p><xref ref-type="bibr" rid="cav.REF.kubisch.2003.512">Kubisch et al [2003]</xref> reported two unrelated individuals with severe RMD. In addition, one individual had overlapping features consistent with LGMD1C.</p>
        <p>Eight of ten patients in the UK with a caveolinopathy had rippling muscle movements [<xref ref-type="bibr" rid="cav.REF.aboumoussa.2008.572">Aboumoussa et al 2008</xref>].</p>
        <p><bold>Distal myopathy (DM).</bold>
<xref ref-type="bibr" rid="cav.REF.tateyama.2002.323">Tateyama et al [2002]</xref> reported one Japanese woman age 25 years with muscle atrophy in her hands and feet, decreased distal muscle function, and normal proximal muscle strength, in whom a <italic toggle="yes">CAV3</italic> mutation (p.Arg26Gln) was identified. Her serum CK concentration was 25 times increased. The distal myopathy may be preceded by hyperckemia and muscle hyperexcitability (percussion-induced rapid contractions) [<xref ref-type="bibr" rid="cav.REF.gonzalezperez.2009.95">Gonzalez-Perez et al 2009</xref>].</p>
        <p><bold>Hypertrophic cardiomyopathy (HCM).</bold>
<xref ref-type="bibr" rid="cav.REF.hayashi.2004.178">Hayashi et al [2004]</xref> described two siblings with hypertrophic cardiomyopathy (HCM). Neither had skeletal muscle manifestations; serum CK concentrations were normal. The caveolin-3 mutation was not found in their mother. Therefore, it was suggested that the mutation was inherited from the father, who had also been affected by HCM but had not been tested, had died at age 41, and had no siblings to be examined. </p>
        <p><bold>Overlapping muscle disease phenotypes.</bold>
<xref ref-type="bibr" rid="cav.REF.fischer.2003.233">Fischer et al [2003]</xref> described family members with different, but overlapping, muscle disease phenotypes. RMD was evident in all 14 affected individuals, 12 of whom had evidence of LGMD or DM and two of whom had only RMD. </p>
        <p>Overlapping phenotypes were also found within two Japanese families; four of six individuals with RMD also had DM [<xref ref-type="bibr" rid="cav.REF.yabe.2003.47">Yabe et al 2003</xref>].</p>
        <p>An Italian family showed the LGMD1C, RMD, and HCK phenotypes [<xref ref-type="bibr" rid="cav.REF.cagliani.2003.1513">Cagliani et al 2003</xref>].</p>
        <p><bold>Other possible phenotypes.</bold>
<italic toggle="yes">CAV3</italic> sequence analysis of 905 persons with long QT syndrome (LQTS) identified six heterozygous missense mutations (in 17 individuals) resulting in amino acid changes in highly conserved residues [<xref ref-type="bibr" rid="cav.REF.vatta.2006.2104">Vatta et al 2006</xref>]. Caveolin-3 associates with the sodium channel in cardiomyocytes, thus suggesting that caveolin-3 could play a role in the regulation of cardiac excitability. Although the patients did not display any sign of cardiomyopathy or muscular disorder, CK measurement and assessment of additional family members are necessary to exclude muscular involvement. Three <italic toggle="yes">CAV3</italic> mutations (p.Val14Leu, p.Thr78Met, p.Leu79Arg) have been reported in three infants who died from sudden infant death syndrome (SIDS) [<xref ref-type="bibr" rid="cav.REF.cronk.2007.161">Cronk et al 2007</xref>].</p>
        <sec id="cav.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations do not exist, as studies have shown that the same mutation can lead to heterogeneous clinical phenotypes and muscle histopathologic changes [<xref ref-type="bibr" rid="cav.REF.fulizio.2005.82">Fulizio et al 2005</xref>]. For example, the <italic toggle="yes">CAV3</italic> mutation p.Thr63Ser found in an individual with HCM is analogous to mutations p.Thr63Pro and &#x00394;TFT (deletion of amino acid residues 63-65) identified in association with LGMD1C. Similarly, the same p.Arg26Gln <italic toggle="yes">CAV3</italic> mutation was reported in a family with phenotypic variability. Of the 11 individuals with the confirmed mutation, three exhibited both RMD and LGMD1C features, two had predominantly LGMD1C features, two had muscle stiffness only, and one was asymptomatic.</p>
          <p>This observed intrafamilial phenotypic variability suggests that other genetic modifiers may exist.</p>
        </sec>
        <sec id="cav.Penetrance">
          <title>Penetrance</title>
          <p><italic toggle="yes">CAV3</italic> mutations are characterized by high penetrance.</p>
          <p><xref ref-type="bibr" rid="cav.REF.fee.2004.375">Fee et al [2004]</xref> described one family including one member with a confirmed p.Arg26Gln mutation and no clinical manifestations of disease at age 86 years.</p>
          <p>Higher penetrance of isolated hyperCKemia (both familial and simplex [i.e., a single occurrence in a family]) has been reported in men [<xref ref-type="bibr" rid="cav.REF.capasso.2006.760">Capasso et al 2006</xref>].</p>
        </sec>
        <sec id="cav.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation is not observed.</p>
        </sec>
        <sec id="cav.Prevalence">
          <title>Prevalence</title>
          <p><xref ref-type="bibr" rid="cav.REF.fulizio.2005.82">Fulizio et al [2005]</xref> and <xref ref-type="bibr" rid="cav.REF.fanin.2009.1432">Fanin et al [2009]</xref> estimated that caveolinopathies account for 1%-2% of unclassified LGMD and other phenotypes including isolated HCK, RMD, and proximal and distal myopathy. </p>
        </sec>
      </sec>
      <sec id="cav.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">CAV3</italic>.</p>
      </sec>
      <sec id="cav.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="dbmd" document-type="chapter">Dystrophinopathies</related-object> are a group of disorders caused by mutations in <italic toggle="yes">DMD</italic>, which encodes the protein dystrophin. The clinical spectrum ranges from mild to severe. Mildly affected individuals can present with subclinical skeletal muscle involvement with hyperCKemia and calf hypertrophy, with or without muscle cramps or myalgia.</p>
        <p>The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne/Becker muscular dystrophy when skeletal muscle is primarily affected and as <italic toggle="yes">DMD</italic>-related dilated cardiomyopathy when the heart is primarily affected. DMD is rapidly progressive, with affected children being wheelchair bound by age 12 years. Cardiomyopathy occurs in all affected individuals after age 18 years. Becker muscular dystrophy (BMD) is characterized by later-onset skeletal muscle weakness; individuals remain ambulatory into their 20s. Despite the milder skeletal muscle involvement in BMD, heart failure from dilated cardiomyopathy (DCM) is common. <italic toggle="yes">DMD</italic>-related dilated cardiomyopathy is characterized by left-ventricular dilation and congestive heart failure. Female carriers of a <italic toggle="yes">DMD</italic> mutation are at increased risk for dilated cardiomyopathy.</p>
        <p>Molecular genetic testing of <italic toggle="yes">DMD</italic> can establish the diagnosis of a dystrophinopathy without muscle biopsy in the majority of cases of DMD and BMD. The dystrophinopathies are inherited in an X-linked manner.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter"><bold>Limb-girdle muscular dystrophy</bold></related-object>
<bold>(LGMD)</bold> is a purely descriptive term, generally reserved for childhood- or adult-onset muscular dystrophies that are distinct from the much more common X-linked dystrophinopathies. Individuals with LGMD generally show weakness and wasting restricted to the limb musculature, proximal greater than distal. Most individuals with LGMD show relative sparing of the heart and bulbar muscles, although exceptions occur, depending on the genetic subtype. The limb-girdle muscular dystrophies typically show degeneration/regeneration of muscle (dystrophic biopsy), which is usually associated with elevated serum creatine kinase concentration. Biochemical testing (i.e., protein testing by immunostaining) performed on a muscle biopsy can establish the diagnosis of the LGMD subtypes sarcoglycanopathy, <related-object link-type="booklink" source-id="gene" document-id="lgmd2a" document-type="chapter">calpainopathy</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="miyoshi" document-type="chapter">dysferlinopathy</related-object>. In some cases, demonstration of complete or partial deficiencies for any particular protein can then be followed by mutation studies of the corresponding gene. </p>
        <p>Although LGMD previously referred to muscular dystrophies inherited in an autosomal recessive manner, it is now recognized that limb-girdle muscular dystrophy also includes rare dominantly inherited subtypes.</p>
        <p><bold>Isolated or familial hyperCKemia.</bold> Raised serum creatine kinase concentration (hyperCKemia) is a hallmark of several neuromuscular diseases. However, hyperCKemia is not specific to neuromuscular diseases and can be found in other diseases or conditions. Among the causes of isolated hyperCKemia that need to be considered are: metabolic and inflammatory disorders, hypothyroidism, malignant hyperthermia (see <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object>), alcoholism, and drug use, as well as following intramuscular injections.</p>
        <p><bold>Myotonic disorders.</bold> Muscle stiffness and clinical signs of increased muscle irritability may be present in myotonic disorders: </p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter">Myotonic dystrophy type 1</related-object>
</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="myotonic-d2" document-type="chapter">Myotonic dystrophy type 2</related-object>
</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="myotonia-c" document-type="chapter">Myotonia congenita</related-object>
</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hyper-pp" document-type="chapter">Hyperkalemic periodic paralysis type 1</related-object> (HyperPP1) </p>
          </list-item>
        </list>
        <p>However, the percussion or rapid pressing of selective muscles (biceps, forearm extensor and flexor, anterior tibial) inducing rapid contraction can be suggestive of RMD. In addition, EMG in persons with RMD does not show the typical myotonic runs of myotonia.</p>
        <p><bold>Distal myopathy.</bold>
<related-object link-type="booklink" source-id="gene" document-id="miyoshi" document-type="chapter">Dysferlinopathy</related-object>, caused by mutations in <italic toggle="yes">DYSF</italic>, includes a spectrum of muscle disease characterized mainly by two phenotypes: </p>
        <list list-type="bullet">
          <list-item>
            <p>Miyoshi myopathy, characterized in young adults by distal muscle weakness and atrophy, most marked in the gastrocnemius and soleus muscles. Over a period of years, weakness and atrophy spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength, but the small muscles of the hands are spared. </p>
          </list-item>
          <list-item>
            <p>Limb-girdle muscular dystrophy syndrome (LGMD2B), characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles in adolescence or young adulthood, with slow progression </p>
          </list-item>
        </list>
        <p>Serum CK concentration is markedly elevated and the muscle biopsy demonstrates signs of a dystrophy with deficiency of dysferlin. Inheritance is autosomal recessive.</p>
      </sec>
      <sec id="cav.Management">
        <title>Management</title>
        <sec id="cav.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with caveolinopathies, initial evaluation includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Orthopedic examination to assess the presence of scoliosis </p>
            </list-item>
            <list-item>
              <p>Analysis of respiratory function: spirometry (patients age &#x0003e;5 years), measurement of arterial pO<sub>2</sub> and pCO<sub>2</sub>, measurement of transcutaneous O<sub>2</sub> saturation </p>
            </list-item>
            <list-item>
              <p>Cardiac examination: 24-hour electrocardiogram and echocardiogram </p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="cav.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>No specific treatment is currently available for caveolinopathies.</p>
          <p>Aggressive supportive care is essential to preserve muscle function, to maximize functional ability, and to treat complications, especially in cases with LGMD features. Management should include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Weight control to avoid obesity </p>
            </list-item>
            <list-item>
              <p>Physical therapy and stretching exercises to promote mobility and prevent contractures </p>
            </list-item>
            <list-item>
              <p>Use of mechanical aids such as canes, walkers, orthotics, and wheelchairs as needed to help ambulation and mobility </p>
            </list-item>
            <list-item>
              <p>Social and emotional support and stimulation to maximize a sense of social involvement and productivity and to reduce the sense of social isolation common in these disorders [<xref ref-type="bibr" rid="cav.REF.eggers.1998.4">Eggers &#x00026; Zatz 1998</xref>] </p>
            </list-item>
          </list>
        </sec>
        <sec id="cav.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>In individuals with isolated hyperCKemia, special precautions during surgical procedures and anesthesia should be considered, despite the fact that malignant hyperthermia (MH) has not been reported in association with <italic toggle="yes">CAV3</italic> mutations. (See <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object>.) </p>
        </sec>
        <sec id="cav.Surveillance">
          <title>Surveillance</title>
          <p>Periodic monitoring of the following is recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Spine: orthopedic consultation and, if needed, x-ray analysis </p>
            </list-item>
            <list-item>
              <p>Respiratory function: spirometry </p>
            </list-item>
            <list-item>
              <p>Cardiac function: 24-hour electrocardiography and echocardiography </p>
            </list-item>
            <list-item>
              <p>Mobility and muscle function: physiatrist and physical therapist consultation </p>
            </list-item>
          </list>
          <p>The interval between visits is determined based on the symptoms and signs observed in the individual patient.</p>
        </sec>
        <sec id="cav.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="cav.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cav.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="cav.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cav.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Most of the caveolinopathies are inherited in an autosomal dominant manner.</p>
          <p>Caveolinopathies may also be inherited in an autosomal recessive manner.</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="bibr" rid="cav.REF.mcnally.1998.871">McNally et al [1998]</xref> found homozygosity for the <italic toggle="yes">CAV3</italic> mutation p.Gly55Ser in one of 82 individuals with muscular dystrophy screened for mutations in <italic toggle="yes">CAV3</italic>. </p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="cav.REF.kubisch.2005.303">Kubisch et al [2005]</xref> described a homozygous amino acid exchange (p.Leu86Pro) in one individual affected by RMD and displaying complete loss of caveolin-3 on muscle biopsy. Clinical and genetic analyses of additional family members were not performed. </p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="cav.REF.muller.2006.432">Muller et al [2006]</xref> reported a patient exhibiting a homozygous splice-site <italic toggle="yes">CAV3</italic> mutation resulting in aberrant splicing, in-frame deletion of 14 amino acids, and loss of caveolin-3 protein at muscle biopsy. The clinical phenotype is compatible with mild LGMD. Sequence analysis and family history indicate an autosomal recessive inheritance. Additional family members were not available for genetic testing. </p>
            </list-item>
          </list>
        </sec>
        <sec id="cav.Risk_to_Family_Members__Autosomal_Do">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with a caveolinopathy have an affected parent. </p>
            </list-item>
            <list-item>
              <p>A proband with a caveolinopathy may have the disorder as the result of a new gene mutation. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutations is unknown, but probably small. </p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> mutation include measurement of serum CK concentration, neuromuscular evaluation, electrophysiologic studies, and molecular genetic testing if the mutation has been identified in the proband. Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of a milder phenotype. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed. </p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with caveolinopathy have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, autosomal recessive inheritance, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents. </p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%. </p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low. </p>
            </list-item>
            <list-item>
              <p>Although no instances of germline mosaicism have been reported, it remains a possibility. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with a caveolinopathy has a 50% chance of inheriting the mutation. </p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members are at risk. </p>
        </sec>
        <sec id="cav.Risk_to_Family_Members__Autosomal_Re">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutant allele. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) can be asymptomatic or can display modest elevation of serum CK levels and/or calf hypertrophy. </p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. </p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) can be asymptomatic or can display modest elevation of serum CK levels and/or calf hypertrophy. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with an autosomal recessive caveolinopathy are obligate heterozygotes (carriers) for a disease-causing mutation in <italic toggle="yes">CAV3</italic>. </p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier. </p>
        </sec>
        <sec id="cav.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible once the mutations have been identified in the family. </p>
        </sec>
        <sec id="cav.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> mutation.</bold> When neither parent of a proband with an autosomal dominant condition has the disease-causing mutation or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> mutation. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling&#x000a0;(including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="cav.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the disease-causing mutation(s) have been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks' gestation) or chorionic villus sampling (usually performed at ~10-12 weeks' gestation). </p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for spme families in which the disease-causing mutation(s) have been identified. </p>
        </sec>
      </sec>
      <sec id="cav.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cav.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="cav.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Caveolin-3 is essential for the biogenesis of caveolae, small invaginations of the muscle plasma membrane that play a critical role in the maintenance of muscle cell structural integrity and signaling.</p>
          <p>The role of caveolae and caveolin-3 in muscle has become clinically relevant with the finding that mutations in <italic toggle="yes">CAV3</italic> are associated with several muscle pathologies including a rare form of LGMD1C, hereditary rippling muscle disease (RMD), distal myopathy (DM), hyperCKemia (HCK), and hypertrophic cardiomyopathy (HCM). Genotype-phenotype correlations do not exist, as studies have shown that the same mutation can lead to heterogeneous clinical phenotypes and muscle histopathologic changes [<xref ref-type="bibr" rid="cav.REF.fulizio.2005.82">Fulizio et al 2005</xref>].</p>
          <p>Phenotypic characterization of the first two <italic toggle="yes">CAV3</italic> mutations identified in individuals with LGMD1C (p.Pro104Leu and &#x00394;TFT [deletion of amino acid residues 63-65]) indicated that these mutants form unstable high-molecular-mass aggregates that are retained in the Golgi complex and are not correctly targeted to the plasma membrane [<xref ref-type="bibr" rid="cav.REF.minetti.1998.365">Minetti et al 1998</xref>, <xref ref-type="bibr" rid="cav.REF.galbiati.1999b.25632">Galbiati et al 1999b</xref>]. Consistent with their autosomal dominant inheritance, these mutations cause retention of wild-type caveolin-3 in the Golgi compartment, thus inducing the proteolysis of wild-type caveolin-3 by ubiquitination and proteasomal degradation [<xref ref-type="bibr" rid="cav.REF.galbiati.1999b.25632">Galbiati et al 1999b</xref>, <xref ref-type="bibr" rid="cav.REF.galbiati.2000.37702">Galbiati et al 2000</xref>]. Moreover, <xref ref-type="bibr" rid="cav.REF.smythe.2003.4739">Smythe et al [2003]</xref> determined that &#x00394;TFT in post-mitotic skeletal myotubes severely reduces the binding of the signal molecule Src to caveolin-3, diminishes targeting of Src to lipid rafts, and causes abnormal perinuclear accumulation of Src. Along with these alterations of Src localization and targeting, Src activation is elevated in myotubes expressing the &#x00394;TFT mutation, and an increased incidence of apoptosis in those cells compared with control myotubes is observed. These results indicate that <italic toggle="yes">CAV3</italic> mutations, by impairing the formation of caveolae at muscle sarcolemma, disrupt normal cellular signal transduction pathways, alter muscle cell structural integrity, and cause apoptosis.</p>
          <p>A similar experimental approach was utilized to complete a functional characterization of the <italic toggle="yes">CAV3</italic> mutation p.Arg26Gln, which was identified in individuals with LGMD1C, RMD, DM, and HCK. The p.Arg26Gln amino acid change decreases the steady-state expression levels of caveolin-3, leads to intracellular retention of the protein in a perinuclear Golgi compartment, and causes caveolin-3 to be partially excluded from lipid rafts/caveolae-enriched membrane domains. However, this mutation does not behave in a dominant-negative fashion because it does not affect the subcellular localization of wild-type caveolin-3 [<xref ref-type="bibr" rid="cav.REF.sotgia.2003b.C1150">Sotgia et al 2003b</xref>]. These data provide a likely explanation for the observed differences in detectable levels of the caveolin-3 protein in human muscle tissue biopsies taken from patients with &#x00394;TFT/p.Pro104Leu mutations (90%-95% reduction in caveolin-3 levels [<xref ref-type="bibr" rid="cav.REF.minetti.1998.365">Minetti et al 1998</xref>]) vs. the p.Arg26Gln mutation (60%-80% reduction in caveolin-3 levels [<xref ref-type="bibr" rid="cav.REF.cagliani.2003.1513">Cagliani et al 2003</xref>]). These differences in the levels and functionality of the remaining wild-type caveolin-3 protein may explain the varied clinical presentations as well.</p>
          <p>It is important to note that individuals with LGMD1C and experimental models of p.Pro104Leu and &#x00394;TFT <italic toggle="yes">CAV3</italic> mutations also manifest mislocalization of dysferlin, a muscle membrane protein that is decreased in Miyoshi myopathy and LGMD2B. In physiologic conditions, dysferlin interacts with caveolin-3 on the muscle sarcolemmma, whereas in the presence of caveolin-3 deficiency it accumulates in the cytoplasm or it displays an irregular "patchy" distribution on the membrane [<xref ref-type="bibr" rid="cav.REF.matsuda.2001.1761">Matsuda et al 2001</xref>, <xref ref-type="bibr" rid="cav.REF.hernandezdeviez.2006.129">Hernandez-Deviez et al 2006</xref>]. <xref ref-type="bibr" rid="cav.REF.selcen.2001.1472">Selcen et al [2001]</xref> indicated striking disruptions of the structure of the sarcolemma in muscle biopsy from individuals with Myoshi myopathy, thus suggesting an important role for dysferlin in muscle cell structure. It is possible that changes in dysferlin cellular localization may contribute to the pathogenesis of caveolin-3 associated disorders. The functional relevance and the mechanisms of action of caveolin-3 in skeletal muscle cells has been further demonstrated by the analysis of the consequences of <italic toggle="yes">CAV3</italic> inactivation both in vitro and in vivo. Antisense inhibition of caveolin-3 expression in cultured skeletal myoblasts precludes myoblast fusion and myotube formation, normal processes of skeletal muscle development [<xref ref-type="bibr" rid="cav.REF.galbiati.1999a.30315">Galbiati et al 1999a</xref>, <xref ref-type="bibr" rid="cav.REF.volonte.2003.4075">Volonte et al 2003</xref>].</p>
          <p>Cav3 knockout mice lack muscle cell caveolae and display a number of myopathic changes consistent with mild muscular dystrophy. Soleus muscle degenerates in the knockout animals by age eight weeks, as does the diaphragm at eight to thirty weeks, but there is otherwise no effect on growth and motor movement relative to wild-type mice. Cav3 +/- hemizygotes have no muscle myopathy, indicating an autosomal recessive transmission of the myopathic phenotype, which contrasts with the dominant-negative Cav3 missense mutations associated with LGMD1C [<xref ref-type="bibr" rid="cav.REF.hagiwara.2000.3047">Hagiwara et al 2000</xref>]. Cav3 -/- mice develop cardiomyopathy characterized by cardiac hypertrophy, dilation, and reduced fractional shortening by age four months. Histologically, the cardiac muscle shows increased cellular infiltration with accompanying perivascular fibrosis [<xref ref-type="bibr" rid="cav.REF.hnasko.2003.445">Hnasko &#x00026; Lisanti 2003</xref>].</p>
          <p><bold>Benign allelic variants.</bold> See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="PDF File" xlink:href="cav-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf) for a list of <italic toggle="yes">CAV3</italic> allelic variants reported to have no noticeable phenotypic effect. </p>
          <p><bold>Pathogenic allelic variants.</bold> To date, 30 point mutations and two microdeletions have been described in <italic toggle="yes">CAV3</italic>. Although the first two mutations discovered, i.e. p.Pro104Leu and &#x00394;TFT, involve two of the 12 residues conserved among all the members of the caveolin protein family, other mutations are not in conserved residues [<xref ref-type="bibr" rid="cav.REF.gazzerro.2010.137">Gazzerro et al 2010</xref>].</p>
          <p>See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="PDF File" xlink:href="cav-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf) for a list of <italic toggle="yes">CAV3</italic> pathogenic allelic variants and associated phenotypes. </p>
          <p><bold>Normal gene product.</bold> Caveolae are vesicular invaginations of the plasma membrane that regulate vesicular trafficking events and signal transduction processes. Caveolins function as scaffolding proteins to organize specific lipids (cholesterol and glycosphingolipids) and signaling molecules (Src-like kinase, Ha-Ras, nitric oxide synthase, and G proteins) within caveolae membranes. </p>
          <p>Caveolin-3 is a muscle-specific membrane protein and the principal component of caveolae membrane in muscle cells in vivo [<xref ref-type="bibr" rid="cav.REF.tang.1996.2255">Tang et al 1996</xref>, <xref ref-type="bibr" rid="cav.REF.way.1996.108">Way &#x00026; Parton 1996</xref>]. Caveolin-3 contains a 20-amino acid scaffolding domain that is critical for homo-oligomerization and for interaction with several caveolin-associated molecules, and a 33-amino acid hydrophobic domain that spans the cell membrane [<xref ref-type="bibr" rid="cav.REF.williams.2004.214">Williams &#x00026; Lisanti 2004</xref>]. During the process of caveolae formation, caveolin-3 undergoes two stages of self-association or oligomerization in the endoplasmic reticulum. Each homo-oligomer contains approximately 14-16 caveolin monomers. At a later stage, the caveolin homo-oligomers interact with each other to form clusters that are approximately 25-50 nm in diameter. </p>
          <p>The expression of caveolin-3 is induced during the differentiation of skeletal myoblast, and caveolin-3 displays several functions in muscle cells. On the muscle sarcolemma it forms a complex with dystrophin and its associated glycoproteins, thus contributing to the structural stability of the plasma membrane [<xref ref-type="bibr" rid="cav.REF.song.1996.15160">Song et al 1996</xref>]. A direct interaction between &#x003b2;-dystroglycan and caveolin-3 has been demonstrated [<xref ref-type="bibr" rid="cav.REF.sotgia.2000.38048">Sotgia et al 2000</xref>]. However, under certain conditions caveolin-3 can be physically separated from the dystrophin complex [<xref ref-type="bibr" rid="cav.REF.crosbie.1998.279">Crosbie et al 1998</xref>]. This indicates that although caveolin-3 is dystrophin associated, it is not absolutely required for the biogenesis of the dystrophin complex. Electron microscopy studies have demonstrated a transient association of caveolin-3 with transverse tubules (T tubules) during differentiation of mouse skeletal fibers. Moreover, on the plasma membrane caveolin-3 interacts with nitric oxide synthase, a molecule that is important for the regulation of muscle contractility and exercise-induced glucose uptake [<xref ref-type="bibr" rid="cav.REF.garciacardena.1997.25437">Garcia-Cardena et al 1997</xref>, <xref ref-type="bibr" rid="cav.REF.williams.2004.214">Williams &#x00026; Lisanti 2004</xref>]. </p>
          <p>In addition to its structural functions, caveolin-3 is required for the insulin receptor-mediated activation of glucose uptake and it regulates the subcellular distribution of phosphofructokinase (PFK), a key enzyme of carbohydrate metabolism [<xref ref-type="bibr" rid="cav.REF.sotgia.2003a.2619">Sotgia et al 2003a</xref>, <xref ref-type="bibr" rid="cav.REF.fecchi.2006.705">Fecchi et al 2006</xref>]. These data indicate that caveolae play a critical role also in the control of energy metabolism of skeletal muscle fibers. </p>
          <p><bold>Abnormal gene product.</bold> Most <italic toggle="yes">CAV3</italic> mutations result in a severe reduction of the caveolin-3 protein in muscle and a loss of caveolae at the sarcolemma.</p>
          <p>Functional studies utilizing overexpression of p.Pro104Leu, &#x00394;TFT, and p.Arg26Gln mutations in a heterologous cell system (NIH3T3) have indicated that these caveolin-3 mutants display an impaired homo-oligomerization, are retained within the Golgi complex, and do not localize at the plasma membrane. In addition, misfolded caveolin-3 oligomers are targeted to proteasomal degradation and can exert a dominant-negative effect on wild-type protein [<xref ref-type="bibr" rid="cav.REF.gazzerro.2010.137">Gazzerro et al 2010</xref>]. </p>
        </sec>
      </sec>
      <sec id="cav.References">
        <title>References</title>
        <sec id="cav.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cav.Literature_Cited.reflist0">
            <ref id="cav.REF.aboumoussa.2008.572">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aboumoussa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoogendijk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charlton</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barresi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton-Jones</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eagle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Caveolinopathy &#x02013; New mutations and additional symptoms.</article-title>
                <source>Neuromuscul Disord</source>
                <year>2008</year>
                <volume>18</volume>
                <fpage>572</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18583131</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.alias.2004.321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alias</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pujol</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Matos</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baiget</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olive</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia.</article-title>
                <source>Neuromuscul Disord</source>
                <year>2004</year>
                <volume>14</volume>
                <fpage>321</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15099591</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.betz.2001.218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Betz</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricker</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramirez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torbergsen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>YA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nothen</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wienker</surname>
                    <given-names>TF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malin</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Propping</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jentsch</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease.</article-title>
                <source>Nat Genet</source>
                <year>2001</year>
                <volume>28</volume>
                <fpage>218</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11431690</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.cagliani.2003.1513">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cagliani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresolin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prelle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallanti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fortunato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sironi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciscato</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fagiolari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <article-title>A CAV3 microdeletion differentially affects skeletal muscle and myocardium.</article-title>
                <source>Neurology</source>
                <year>2003</year>
                <volume>61</volume>
                <fpage>1513</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14663034</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.capasso.2006.760">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Capasso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Angelis</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Muzio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarciolla</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pace</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuppia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uncini</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Familial idiopathic hyper-CK-emia: an underrecognized condition.</article-title>
                <source>Muscle Nerve</source>
                <year>2006</year>
                <volume>33</volume>
                <fpage>760</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16502425</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.carbone.2000.1373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bado</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broda</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masetti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panella</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bricarelli</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordone</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia.</article-title>
                <source>Neurology</source>
                <year>2000</year>
                <volume>54</volume>
                <fpage>1373</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10746614</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.cronk.2007.161">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cronk</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaku</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tester</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vatta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makielski</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerman</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>Novel mechanism for sudden infant death syndrome: Persistent late sodium current secondary to mutations in caveolin-3.</article-title>
                <source>Heart Rhythm</source>
                <year>2007</year>
                <volume>4</volume>
                <fpage>161</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17275750</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.crosbie.1998.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Crosbie</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venzke</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <article-title>Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.</article-title>
                <source>FEBS Lett</source>
                <year>1998</year>
                <volume>427</volume>
                <fpage>279</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">9607328</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.eggers.1998.4">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eggers</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zatz</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Social adjustment in adult males affected with progressive muscular dystrophy.</article-title>
                <source>Am J Med Genet.</source>
                <year>1998</year>
                <volume>81</volume>
                <fpage>4</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">9514580</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.fanin.2009.1432">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fanin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nascimbeni</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aurino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tasca</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pegoraro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nigro</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Frequency of LGMD gene mutations in Italian patients with distinct clinical genotypes.</article-title>
                <source>Neurology</source>
                <year>2009</year>
                <volume>72</volume>
                <fpage>1432</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19380703</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.fecchi.2006.705">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fecchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volonte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hezel</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmeck</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Spatial and temporal regulation of GLUT4 translocation by flotillin-1 and caveolin-3 in skeletal muscle cells.</article-title>
                <source>FASEB J</source>
                <year>2006</year>
                <volume>20</volume>
                <fpage>705</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16455755</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.fee.2004.375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fee</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>So</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barraza</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueroa</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulst</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <article-title>Phenotypic variability associated with Arg26Gln mutation in caveolin3.</article-title>
                <source>Muscle Nerve</source>
                <year>2004</year>
                <volume>30</volume>
                <fpage>375</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15318349</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.figarellabranger.2003.562">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Figarella-Branger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouget</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernard</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krahn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellissier</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <article-title>Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene.</article-title>
                <source>Neurology</source>
                <year>2003</year>
                <volume>61</volume>
                <fpage>562</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12939441</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.fischer.2003.233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumcke</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urbach</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Consequences of a novel caveolin-3 mutation in a large German family.</article-title>
                <source>Ann Neurol</source>
                <year>2003</year>
                <volume>53</volume>
                <fpage>233</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">12557291</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.fulizio.2005.82">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fulizio</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiara Nascimbeni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fanin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piluso</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Politano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nigro</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Molecular and muscle pathology in a series of caveolinopathy patients.</article-title>
                <source>Hum Mutat</source>
                <year>2005</year>
                <volume>25</volume>
                <fpage>82</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15580566</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.galbiati.1999a.30315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volonte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelman</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation.</article-title>
                <source>J Biol Chem</source>
                <year>1999a</year>
                <volume>274</volume>
                <fpage>30315</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">10514527</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.galbiati.2000.37702">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volonte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bregman</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.</article-title>
                <source>J Biol Chem</source>
                <year>2000</year>
                <volume>275</volume>
                <fpage>37702</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">10973975</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.galbiati.1999b.25632">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volonte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.</article-title>
                <source>J Biol Chem</source>
                <year>1999b</year>
                <volume>274</volume>
                <fpage>25632</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">10464299</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.garciacardena.1997.25437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garcia-Cardena</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martasek</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masters</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skidd</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couet</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sessa</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <article-title>Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo.</article-title>
                <source>J Biol Chem</source>
                <year>1997</year>
                <volume>272</volume>
                <fpage>25437</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">9325253</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.gazzerro.2010.137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gazzerro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Caveolinopathies: from the biology of caveolin-3 to human diseases.</article-title>
                <source>European Journal of Human Genetics</source>
                <year>2010</year>
                <volume>18</volume>
                <fpage>137</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">19584897</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.gonzalezperez.2009.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonzalez-Perez</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez-Quereda</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivas-Infante</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teijeira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bautista-Lorite</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Phenotypic variability in a Spanish family with a Caveolin-3 mutation.</article-title>
                <source>Journal Neurological Sciences</source>
                <year>2009</year>
                <volume>276</volume>
                <fpage>95</fpage>
                <lpage>8</lpage>
              </element-citation>
            </ref>
            <ref id="cav.REF.hagiwara.2000.3047">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagiwara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaoka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Araishi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yorifuji</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozawa</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Caveolin-3 deficiency causes muscle degeneration in mice.</article-title>
                <source>Hum Mol Genet</source>
                <year>2000</year>
                <volume>9</volume>
                <fpage>3047</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11115849</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.hayashi.2004.178">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arimura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shibata</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hohda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hori</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koga</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oka</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imaizumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasunami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <year>2004</year>
                <volume>313</volume>
                <fpage>178</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">14672715</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.hernandezdeviez.2006.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hernandez-Deviez</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laval</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lo</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>North</surname>
                    <given-names>KN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parton</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3.</article-title>
                <source>Hum Mol Genet</source>
                <year>2006</year>
                <volume>15</volume>
                <fpage>129</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">16319126</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.herrmann.2000.2335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herrmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blank</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutzick</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franke</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>EN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenard</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy.</article-title>
                <source>Hum Mol Genet</source>
                <year>2000</year>
                <volume>9</volume>
                <fpage>2335</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">11001938</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.hnasko.2003.445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hnasko</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>The biology of caveolae: lessons from caveolin knockout mice and implications for human disease.</article-title>
                <source>Mol Interv.</source>
                <year>2003</year>
                <volume>3</volume>
                <fpage>445</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">14993453</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.kubisch.2005.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ketelsen</surname>
                    <given-names>UP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goebel</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omran</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal recessive rippling muscle disease with homozygous CAV3 mutations.</article-title>
                <source>Ann Neurol</source>
                <year>2005</year>
                <volume>57</volume>
                <fpage>303</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15668980</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.kubisch.2003.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von During</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betz</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goebel</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zahn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrbrecht</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aasly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovic</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lochmuller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruning</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malin</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fricke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meinck</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torbergsen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engels</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease.</article-title>
                <source>Ann Neurol</source>
                <year>2003</year>
                <volume>53</volume>
                <fpage>512</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">12666119</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.kunkel.1999.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kunkel</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Caveolin-3 deficiency as a cause of limb-girdle muscular dystrophy.</article-title>
                <source>J Child Neurol</source>
                <year>1999</year>
                <volume>14</volume>
                <fpage>33</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10223848</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.matsuda.2001.1761">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murayama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arahata</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <article-title>The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle.</article-title>
                <source>Hum Mol Genet</source>
                <year>2001</year>
                <volume>10</volume>
                <fpage>1761</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11532985</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.mcnally.1998.871">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McNally</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sa Moreira</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duggan</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lidov</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vainzof</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passos-Bueno</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zatz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunkel</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <article-title>Caveolin-3 in muscular dystrophy.</article-title>
                <source>Hum Mol Genet</source>
                <year>1998</year>
                <volume>7</volume>
                <fpage>871</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9536092</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.merlini.2002.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capanni</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabatelli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortorelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <year>2002</year>
                <volume>73</volume>
                <fpage>65</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12082049</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.minetti.1998.365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scartezzini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broda</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bado</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masetti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egeo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volonte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordone</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bricarelli</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy.</article-title>
                <source>Nat Genet</source>
                <year>1998</year>
                <volume>18</volume>
                <fpage>365</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9537420</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.muller.2006.432">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piko</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlotter-Weigel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilich</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurster</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Born</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karcagi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongratz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lochmuller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Novel splice site mutation in the caveolin-3 gene leading to autosomal recessive limb girdle muscular dystrophy.</article-title>
                <source>Neuromuscul Disord</source>
                <year>2006</year>
                <volume>16</volume>
                <fpage>432</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16730439</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.schara.2002.483">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schara</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovic</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricker</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Rippling muscle disease in childhood.</article-title>
                <source>J Child Neurol</source>
                <year>2002</year>
                <volume>17</volume>
                <fpage>483</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">12269726</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.selcen.2001.1472">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Selcen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stilling</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>AG</given-names>
                  </name>
                </person-group>
                <article-title>The earliest pathologic alterations in dysferlinopathy.</article-title>
                <source>Neurology</source>
                <year>2001</year>
                <volume>56</volume>
                <fpage>1472</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">11402103</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.smythe.2003.4739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smythe</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eby</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Disatnik</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rando</surname>
                    <given-names>TA</given-names>
                  </name>
                </person-group>
                <article-title>A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.</article-title>
                <source>J Cell Sci</source>
                <year>2003</year>
                <volume>116</volume>
                <fpage>4739</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">14600260</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.song.1996.15160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chafel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohtz</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins.</article-title>
                <source>J Biol Chem</source>
                <year>1996</year>
                <volume>271</volume>
                <fpage>15160</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">8663016</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.sotgia.2003a.2619">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonuccelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodman</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capozza</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemp</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases.</article-title>
                <source>Am J Pathol</source>
                <year>2003a</year>
                <volume>163</volume>
                <fpage>2619</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">14633633</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.sotgia.2000.38048">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bedford</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucci</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macioce</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sargiacomo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bricarelli</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sudol</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members.</article-title>
                <source>J Biol Chem.</source>
                <year>2000</year>
                <volume>275</volume>
                <fpage>38048</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">10988290</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.sotgia.2003b.C1150">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodman</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonuccelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capozza</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.</article-title>
                <source>Am J Physiol Cell Physiol</source>
                <year>2003b</year>
                <volume>285</volume>
                <fpage>C1150</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">12839838</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.sugie.2004.810">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sugie</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murayama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mochizuki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Two novel CAV3 gene mutations in Japanese families.</article-title>
                <source>Neuromuscul Disord</source>
                <year>2004</year>
                <volume>14</volume>
                <fpage>810</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15564037</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.tang.1996.2255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohtz</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimoto</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lodish</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle.</article-title>
                <source>J Biol Chem</source>
                <year>1996</year>
                <volume>271</volume>
                <fpage>2255</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">8567687</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.tateyama.2002.323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tateyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekiguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiga</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onodera</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haginoya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iinuma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arahata</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoyama</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy.</article-title>
                <source>Neurology</source>
                <year>2002</year>
                <volume>58</volume>
                <fpage>323</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11805270</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.traverso.2008.735">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Traverso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broccolini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assereto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gazzerro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lo Monaco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Modoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasperini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Truncation of Caveolin-3 causes autosomal-recessive Rippling Muscle Disease.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2008</year>
                <volume>79</volume>
                <fpage>735</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18487559</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.vandenbergh.2004.1349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van den Bergh</surname>
                    <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerard</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elosegi</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manto</surname>
                    <given-names>MU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <article-title>Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <year>2004</year>
                <volume>75</volume>
                <fpage>1349</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">15314133</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.vatta.2006.2104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vatta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makielski</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ughanze</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tester</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balijepalli</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foell</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamp</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towbin</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome.</article-title>
                <source>Circulation</source>
                <year>2006</year>
                <volume>114</volume>
                <fpage>2104</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">17060380</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.volonte.2003.4075">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Volonte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peoples</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.</article-title>
                <source>Mol Biol Cell</source>
                <year>2003</year>
                <volume>14</volume>
                <fpage>4075</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">14517320</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.vorgerd.2001.2273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricker</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziemssen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kress</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goebel</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nix</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation.</article-title>
                <source>Neurology</source>
                <year>2001</year>
                <volume>57</volume>
                <fpage>2273</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11756609</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.way.1996.108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Way</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parton</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>M-caveolin, a muscle-specific caveolin-related protein.</article-title>
                <source>FEBS Lett.</source>
                <year>1996</year>
                <volume>378</volume>
                <fpage>108</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">8549793</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.williams.2004.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>The caveolin proteins.</article-title>
                <source>Genome Biol</source>
                <year>2004</year>
                <volume>5</volume>
                <fpage>214</fpage>
                <pub-id pub-id-type="pmid">15003112</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.woodman.2004.538">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woodman</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotgia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galbiati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisanti</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases.</article-title>
                <source>Neurology</source>
                <year>2004</year>
                <volume>62</volume>
                <fpage>538</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">14981167</pub-id>
              </element-citation>
            </ref>
            <ref id="cav.REF.yabe.2003.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yabe</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawashima</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukazawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tashiro</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Caveolin-3 gene mutation in Japanese with rippling muscle disease.</article-title>
                <source>Acta Neurol Scand</source>
                <year>2003</year>
                <volume>108</volume>
                <fpage>47</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">12807393</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cav.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cav.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Drs. Sotgia and Lisanti were supported by grants from the Muscular Dystrophy Association (MDA USA) and the National Institutes of Health (NIAMS).</p>
          <p>Drs. Bruno, Gazzerro, and Minetti were supported by grants from Telethon-Italia and the Italian Ministry of Health. </p>
        </sec>
        <sec id="cav.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>6 September 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>14 May 2007 (me) Review posted to live Web site </p>
            </list-item>
            <list-item>
              <p>30 March 2005 (mpl) Original submission </p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
